Monitor the upcoming annual meeting for shareholder sentiment on board changes. David King’s nomination suggests a continued focus on healthcare commercialization and regulatory strategy, which may influence future governance and operational direction.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $127.39entry
- T+1 · 8mo ago −0.03%α −0.51% · $127.35
- T+5 · 7mo ago −5.39%α −9.01% · $120.52
- T+20 · 7mo ago −0.51%α −10.38% · $126.74
- T+60 · 5mo ago +42.17%α +29.18% · $181.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Illumina announced that three board members, Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart, will retire at the 2026 annual meeting, and David P. King has been nominated to join the board. The departures are described as retirements with no disputes, and King brings extensive healthcare leadership experience.
Key Facts
- Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart are retiring from Illumina's Board of Directors effective May 21, 2026.
- The retirements are not due to any disagreement with the company.
- David P. King, former CEO of LabCorp and current board chair at Privia Health and AmSurg, has been nominated to replace them.
- The changes will be voted on at the 2026 annual meeting of stockholders.
Financial Impact
No direct financial impact disclosed. Board refreshment expected to support long-term strategy.
Risk Factors
- Potential loss of scientific and technical expertise from departing directors, particularly Dr. Arnold, a Nobel laureate in chemistry.
- Transition risk if new director does not integrate smoothly into board dynamics.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001110803-26-000082 |
| Exhibit: ex991pressrelease4226.htm | 0001110803-26-000082 |
| Document: 0001110803-26-000082-index-headers.html | 0001110803-26-000082 |
| Document: 0001110803-26-000082-index.html | 0001110803-26-000082 |
| Document: 0001110803-26-000082.txt | 0001110803-26-000082 |
Track record
29 reports on ILMN
3 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +35.34% at T+60 after the May 14, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $207.01 Now $198.00 −4.35% settles Nov 20
- Nov 12, 20264d ago Insider Cluster Bearish 4/10 Entry $207.01 Now $198.00 +4.35% settles Nov 20
- Nov 10, 20266d ago 144 Neutral 4/10 Entry $212.93 Now $198.00 −7.01% settles Nov 18
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $212.93 Now $198.00 −7.01% settles Nov 18
- Nov 3, 202613d ago 144 Neutral 4/10 Entry $226.54 to $212.93 Now $198.00 −12.60% ▼ −6.01% −5.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $235.99 to $213.13 Now $198.00 −16.10% ▼ −9.69% −6.98% vs SPY
- Oct 30, 202618d ago Court Ruling Bullish 5/10 Entry $226.58 to $220.78 Now $198.00 −12.61% ▼ −2.56% −2.64% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $235.99 to $213.13 Now $198.00 −16.10% ▼ −9.69% −6.98% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $288.79 to $226.54 Now $198.00 −31.44% ▼ −21.56% −20.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers